Abstract
We report cutaneous adverse effects developed in three patients and are probably related to Iressa® (Gefitinib, ZD1839) medication. Iressa® is a new anti-cancer agent which acts by inhibiting epidermal growth factor (EGF) receptor signal transduction. The three patients had all taken Iressa® for treatment of non-small cell lung cancer and came to our clinic with cutaneous adverse effects. All three patients had acneiform eruptions, and one of the patients also had periungal granulation lesions. Histopathologically, periadnexal inflammatory cellular infiltrations were seen in the acneiform lesions of the three patients and granulation-like tissue proliferations in periungal granulation lesions of the one patient.
| Original language | English |
|---|---|
| Pages (from-to) | 92-95 |
| Number of pages | 4 |
| Journal | Korean Journal of Dermatology |
| Volume | 43 |
| Issue number | 1 |
| State | Published - Jan 2005 |
| Externally published | Yes |
Keywords
- Acneiform eruption
- Cutaneous adverse effects
- Iressa® (Gefitinib)
- Periungal granulation lesion
